Differences in Inflammatory Marker Kinetics between the First and Second Wave of COVID-19 Patients Admitted to the ICU: A Retrospective, Single-Center Study

• Published in: Journal of clinical medicine 2021-07, Vol.10 (15), p.3290
• Main Authors: Szakmany, Tamas, Tuckwell, William, Harte, Elsa, Wetherall, Nick, Ramachandran, Saraswathi, Price, Shannon, Breen, Henry, Killick, Charlotte, Cheema, Yusuf, King, Charles, Richards, Owen
• Format: Article
• Language: English
• Subjects: Biomarkers; Clinical medicine; Coronaviruses; COVID-19; Mortality
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm10153290

Background: We sought to determine if there was a difference in the longitudinal inflammatory response measured by white blood cell count (WBC), C-reactive protein (CRP), procalcitonin (PCT), and ferritin levels between the first and the second COVID-19 wave of ICU patients. Methods: In a single-center retrospective observational study, ICU patients were enrolled during the first and second waves of the COVID-19 pandemic. Data were collected on patient demographics, comorbidities, laboratory results, management strategies, and complications during the ICU stay. The inflammatory response was evaluated using WBC count, CRP, PCT, and Ferritin levels on the day of admission until Day 28, respectively. Organ dysfunction was measured by the SOFA score. Results: 65 patients were admitted during the first and 113 patients during the second wave. WBC and ferritin levels were higher in the second wave. CRP and PCT showed markedly different longitudinal kinetics up until day 28 of ICU stay between the first and second wave, with significantly lower levels in the second wave. Steroid and immunomodulatory therapy use was significantly greater in the second wave. Mortality was similar in both waves. Conclusions: We found that there was a significantly reduced inflammatory response in the second wave, which is likely to be attributable to the more widespread use of immunomodulatory therapies.